A Randomized Phase 2 Study of Subcutaneous Daratumumab Plus Carfilzomib/Dexamethasone Versus Carfilzomib/Dexamethasone Alone in Patients with Multiple Myeloma who have been Previously Treated with Intravenous Daratumumab to Evaluate Retreatment (LYNX)-MedSci.cn

A Randomized Phase 2 Study of Subcutaneous Daratumumab Plus Carfilzomib/Dexamethasone Versus Carfilzomib/Dexamethasone Alone in Patients with Multiple Myeloma who have been Previously Treated with Intravenous Daratumumab to Evaluate Retreatment (LYNX)

Bahlis, NJ; Zonder, JA; Wroblewski, S; Qi, M; Renaud, T; Jackson, C; Facon, T

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019; 19 (10): E246

科室
- - 订阅+
  - 更多科室
工具
服务